Currently, there are 51.51M common shares owned by the public and among those 47.14M shares have been available to trade.
The company’s stock has a 5-day price change of 90.38% and 45.16% over the past three months. TSVT shares are trading 68.37% year to date (YTD), with the 12-month market performance down to -7.99% lower. It has a 12-month low price of $2.29 and touched a high of $5.99 over the same period. TSVT has an average intraday trading volume of 334.97K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 82.72%, 85.77%, and 27.18% respectively.
Institutional ownership of 2seventy bio Inc (NASDAQ: TSVT) shares accounts for 86.92% of the company’s 51.51M shares outstanding.
It has a market capitalization of $255.36M and a beta (3y monthly) value of 1.60. The earnings-per-share (ttm) stands at -$1.86. Price movements for the stock have been influenced by the stock’s volatility, which stands at 7.09% over the week and 7.83% over the month.
Earnings per share for the fiscal year are expected to increase by 81.00%, and 52.38% over the next financial year.
Looking at the support for the TSVT, a number of firms have released research notes about the stock. Goldman stated their Sell rating for the stock in a research note on June 06, 2024, with the firm’s price target at $5-$2. Leerink Partners coverage for the 2seventy bio Inc (TSVT) stock in a research note released on January 31, 2024 offered a Outperform rating with a price target of $18. TD Cowen was of a view on January 31, 2024 that the stock is Market Perform, while Leerink Partners gave the stock Market Perform rating on October 30, 2023, issuing a price target of $6. Citigroup on their part issued Buy rating on October 12, 2023.
